3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
6
Neoplasm Metastasis
4
Colonic Neoplasms
4
Rectal Neoplasms
3
Stomach Neoplasms
2
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Disease Progression
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Bile Duct Neoplasms
1
Interventions
Gemcitabine
8
Fluorouracil
5
Cisplatin
5
Leucovorin
4
Oxaliplatin
3
becatecarin
2
Capecitabine
2
seribantumab
1
sargramostim
1
pembrolizumab
1
pazopanib
1
motexafin lutetium
1
ixabepilone
1
irinotecan sucrosofate
1
incomplete Freund's adjuvant
1
durvalumab
1
devimistat
1
cediranib
1
Trastuzumab
1
Sorafenib
1
Radiosurgery
1
Psychiatric Rehabilitation
1
Palonosetron
1
Observation
1
Liver Transplantation
1
Folfox protocol
1
Escitalopram
1
Erlotinib Hydrochloride
1
Carboplatin
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Gallbladder Neoplasms
×
Folfox protocol
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts